IMO it is more basic. The issue is re-engaging with the investment community as the new CEO pointed out. As it looks right now the process is initiated. Hence it is not clear why they de-engaged in the first place as the former CEO, POS Mills, did put it. He was saying Q3 last year that he successfully managed "a three-year process of deleveraging the company". That seemed to be his only objective.
I think they should stay on heart (incl veins). Stop VT results will be great. The academic group/experts pushed the company a lot documenting a strong need to do it robotically with stxs. The mortality rate in manual procedures is extremly high. Brain will take a long time imo, the stxs systems currently only used in animal research in the US and Europe.
Bottom line there is no robotic competition. Valuation is basically zero. IR, customer and partner focus will be key. IR requires a CFO that can handle/do it.
Bottom line: Will investors get in or not is the issue. All other companies in the robotic medical space can manage it perfectly, e.g. cvrs and others. As such it should be an easy task. De-engaging was managed successfully (Mills/Stammer)...Re-engaging should be successful as well, simply bc no other company is out there to be able to offer something like the stereotaxis system and they operate in a hot and big market.